AKEEGA

This brand name is authorized in Austria, Croatia, France, Lithuania.

Active ingredients

The drug AKEEGA contains a combination of these active pharmaceutical ingredients (APIs):

1	Niraparib UNII 195Q483UZD - NIRAPARIB TOSYLATE MONOHYDRATE
	Niraparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair.
	Read more about Niraparib
2	Abiraterone UNII EM5OCB9YJ6 - ABIRATERONE ACETATE
	Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals.
	Read more about Abiraterone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AKEEGA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XK52		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors
Discover more medicines within L01XK52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
FR	Base de données publique des médicaments	66855480, 69324990
LT	Valstybinė vaistų kontrolės tarnyba	1097018, 1097019